Two proteins, Aplp1 and Lag3, pair to allow toxic aggregates of alpha-synuclein — a hallmark of Parkinson’s disease — into nerve cells and help it spread across the brain, according to a study in mice. “Now that we know how Aplp1 and Lag3 interact, we have a new way…
BrainTale’s noninvasive imaging analysis software, BrainTale-care, may be able to distinguish Parkinson’s disease from atypical parkinsonism. That’s according to data from an advanced MRI technique, called diffusion tensor imaging, that measures the diffusion of water molecules in the brain’s white matter. White matter contains nerve fibers…
People with Parkinson’s disease who don’t always take Nourianz (istradefylline) as prescribed are more likely to have fewer prescriptions for other approved medications and to have anxiety, mood changes, or cognitive problems, a study finds. Understanding how well patients follow the instructions for taking Nourianz, such as how…
An imaging agent for positron emission tomography (PET) scans allowed researchers to visualize, for the first time, abnormal alpha-synuclein protein clumps in the brains of living patients with Parkinson’s disease, a study showed. By detecting a hallmark feature of Parkinson’s found in relatively lower abundance in the brain compared…
Scientists at the Imperial College London in England have been awarded nearly £100,000, or about $125,000, by Parkinson’s UK to identify new therapeutic targets for Parkinson’s disease. The grant was awarded to Michael Johnson, PhD, and his team, and will fund efforts to harness the power of computers…
Once-daily treatment with Gain Therapeutics‘ GT-02287 rescued motor function and cognitive performance in a mouse model of Parkinson’s disease associated with mutations in the GBA1 gene. “These data further confirm our conviction that GT-02287 can slow or stop progression of Parkinson’s disease and given the cognitive decline observed…
The risk of developing Parkinson’s disease is double in adults older than 50 with anxiety relative to those without it in a recent U.K. study. Other Parkinson’s-associated symptoms, such as sleep issues, constipation, and tremors, were also associated with an elevated Parkinson’s risk in people with anxiety. “By understanding…
Kannalife Sciences has been awarded a $1.49 million grant from The Michael J. Fox Foundation (MJFF) to support the development of KLS-13019, the company’s novel cannabidiol- or CBD-derived therapy targeting neuroinflammation and mitochondrial dysfunction in Parkinson’s disease. KLS-13019 has shown promising results in preclinical models of…
The Aligning Science Across Parkinson’s (ASAP) initiative has launched a data-sharing platform that will make data on human brain samples available to researchers around the world, furthering research into Parkinson’s disease. The ASAP CRN Cloud includes several brain sequencing collections obtained from samples from four ASAP Collaborative…
The U.S. Food and Drug Administration (FDA) has given Iregene Therapeutics the green light to launch a clinical trial testing its cell therapy NouvNeu001, being developed for moderate to advanced Parkinson’s disease. According to the company, this marks a significant milestone, with NouvNeu001 becoming the world’s first…
Get regular updates to your inbox.
